Evaluation of Pancreatic Cancer Screening Accuracy Using C. elegans-Based Cancer Test (N-NOSE) and Tumor Markers

Evaluation of Pancreatic Cancer Screening Accuracy Using C. elegans-Based Cancer Test (N-NOSE) and Tumor Markers - Evaluation of Pancreatic Cancer Screening Accuracy Using C. elegans-Based Cancer Test (N-NOSE) and Tumor Markers

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057117

Enrollment

160

Registered

2025-02-22

Start date

2020-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients hospitalized or receiving outpatient care at the Division of Gastroenterology, Showa University Hospital, diagnosed with pancreatic cancer, pancreatic mass, pancreatic cystic lesions, pancreatic duct dilation, or chronic pancreatitis. Patients aged 20 years or older at the time of consent acquisition. Patients who have provided written informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: Patients with malignancies other than pancreatic cancer. Patients with a history of cancer. Patients deemed ineligible by the principal investigator based on clinical judgment.

Design outcomes

Primary

Measure	Time frame
The discriminatory ability (ROC) of the N-NOSE index and tumor marker values in distinguishing cancer from non-cancer will be analyzed based on cancer stage and tumor location.	—

Countries

Japan

Contacts

Public ContactKazuya Inoki

Department of Medicine, Showa University School of Medicine Division of Gastroenterology

kinoki@med.showa-u.ac.jp0337848535

Outcome results